Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates

Patients treated with bioproducts (BPs) frequently develop anti-drug antibodies (ADAs) with potential neutralizing capacities leading to loss of clinical response or potential hypersensitivity reactions. Many factors can influence BP immunogenicity and could be related to the patient, the treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabhan, Myriam, Pallardy, Marc, Turbica, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214678/
https://www.ncbi.nlm.nih.gov/pubmed/32431697
http://dx.doi.org/10.3389/fimmu.2020.00725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214678/
https://www.ncbi.nlm.nih.gov/pubmed/32431697
http://dx.doi.org/10.3389/fimmu.2020.00725

Ejemplares similares